Table 1.
Baseline characteristics and gender comparisons in the present study.
| All (n = 1,410) | Men (n = 256) | Women (n = 1,154) | P-value | |
|---|---|---|---|---|
| Age, mean ± SD | 48.3 ± 11.5 | 49.6 ± 1.1 | 48.0 ± 11.3 | 0.038 |
| Duration of migraine history (years), mean ± SD | 24.7 ± 14.6 | 23.9 ± 23.6 | 24.8 ± 13.0 | 0.769 |
| Chronic migraine, n (%) | 1,036 (73.5) | 169 (66.0) | 867 (75.1) | 0.002 |
| Medication overuse, n (%) | 733 (52.0) | 133 (52.0) | 600 (52.0) | 0.830 |
| Failed prior preventive drugs, mean ± SD | 5.5 ± 3.0 | 5.5 ± 3.0 | 5.5 ± 2.9 | 0.941 |
| Monthly headache days, mean ± SD | 21.2 ± 7.5 | 20.2 ± 7.4 | 21.4 ± 7.5 | 0.028 |
| Monthly migraine days, mean ± SD | 17.1 ± 8.0 | 16.8 ± 7.7 | 17.2 ± 8.0 | 0.453 |
| Monthly acute medication days, mean ± SD | 16.2 ± 8.5 | 16.1 ± 8.4 | 16.2 ± 8.5 | 0.862 |
| Monthly triptan use days, mean ± SD | 10.9 ± 9.8 | 11.2 ± 9.9 | 10.9 ± 9.8 | 0.768 |
| HIT-6 score, mean ± SD | 66.7 ± 6.6 | 65.0 ± 6.1 | 67.1 ± 6.7 | <0.001 |
P values in bold highlight significant results. HIT-6, Headache Impact Test-6; SD, standard deviation.